CDK4 and breast cancer: Additionally, the loss or inactivating mutations in the FAT1 tumor suppressor gene, an inhibitor of the Hippo pathway, lead to the enrichment of YAP/TAZ transcription factors on the CDK6 promoter, resulting in its increased expression and CDK4/6i failure in ER+ BC [49].